T2 Biosystems to Participate at Clinical Conferences in June and July 2021

Company will underscore the importance of rapid diagnostic technology for detecting bloodstream infections (BSIs) and sepsis

LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company’s participation in three virtual conferences this summer.

The Company will take part in the American Society for Microbiology’s (ASM) and Federation of European Microbiological Societies’ (FEMS) World Microbe Forum; Sepsis Alliance’s inaugural Sepsis Tech and Innovation 2021 conference; and the European Society of Clinical Microbiology and Infectious Diseases’ (ESCMID) 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

“Nearly 20 percent of all global deaths are due to sepsis, and managing it is very costly for hospitals, making sepsis a top priority for industry professionals to tackle,” said CEO John Sperzel. “We’re looking forward to connecting with like-minded peers in the global medical community to discuss how our rapid diagnostic technology can be more effective than standard blood cultures to reach our common goal of better managing bloodstream infections and sepsis.”

At the World Microbe Forum, taking place June 20-24, T2 Biosystems’ Chief Medical Officer, Dr. Aparna Ahuja, will join Dr. James Snyder from the University of Louisville Hospital and Dr. Todd McCarty from the University of Alabama School of Medicine to present the Industry and Science Symposia, “Culture Independent Rapid Diagnostics Impact on Sepsis Management.” They will discuss the implementation process of T2 Biosystems’ T2Candida® Panel and T2Bacteria® Panel, and will specifically highlight the T2Candida® Panel’s utilization impact on clinical outcomes. The presentation will be available to view on-demand beginning on June 20^th at 12:30pm ET on the World Microbe Forum portal.

On June 23 at 2:45 p.m. EDT during the inaugural Sepsis Tech & Innovation conference, Dr. Ahuja and Dr. Debbie Goff from Ohio State University will deliver the Industry Keynote, “Breaking New Ground in Sepsis Diagnosis and Management with Non-Culture-Based Tests.” They will cover the impact of sepsis on health care costs and patient outcomes as well as the critical importance of time to appropriate therapy in sepsis patients.

Lastly, on July 12 at 9:30 a.m. CET during ECCMID, Dr. Thomas Walsh from Weill Cornell Medicine and Dr. Tamara Seitz from SMZ Süd Vienna will join Dr. Ahuja, to participate in the Integrated Symposium, “The Crucial Role of Rapid Diagnostics in the Early Detection of Secondary Bacterial and Fungal Infections Complicating COVID-19.”

T2 Biosystems is committed to overcoming the challenges associated with diagnosing and treating BSIs and sepsis, namely due to the lengthy time it currently takes to receive blood culture results, which typically takes days. T2 Biosystems’ T2Bacteria® and T2Candida® panels use T2MR® technology and provide results directly from whole blood. They are the only FDA-cleared tests to identify sepsis-​causing pathogens directly from whole blood without the wait for blood culture. This enables rapid, targeted therapy, which can help save lives and reduce hospital costs.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance^TM Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris^TM Panel, and T2Lyme ^TM Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of T2 Biosystems products to save lives and reduce hospital costs, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials;  (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes;  (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Media Contact:
Amanda Michelson, Vault Communications
amichelson@vaultcommunications.com 
609-417-7077

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com 
415-937-5406